Montelukast API Market Research Report Information By Application (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, and Others), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035
As per Market Research Future analysis, the Montelukast API Market Size was estimated at 1.01 USD Billion in 2024. The Montelukast API industry is projected to grow from 1.119 USD Billion in 2025 to 3.121 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.8% during the forecast period 2025 - 2035
The Montelukast API Market is poised for growth driven by increasing demand for respiratory treatments and technological advancements.
| 2024 Market Size | 1.01 (USD Billion) |
| 2035 Market Size | 3.121 (USD Billion) |
| CAGR (2025 - 2035) | 10.8% |
Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (IL), Mylan N.V. (NL), Sandoz International GmbH (CH), Aurobindo Pharma(IN), Cipla Limited (IN), Hikma Pharmaceuticals PLC (GB), Zydus Cadila (IN)
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry
The Montelukast API Market is currently experiencing a dynamic phase characterized by evolving demand and regulatory landscapes. As healthcare systems worldwide increasingly prioritize respiratory health, the need for effective treatments for conditions such as asthma and allergic rhinitis has surged. This trend appears to be driven by a growing awareness of the importance of managing chronic respiratory diseases, which may lead to a sustained increase in the consumption of Montelukast API Market. Furthermore, the market seems to be influenced by advancements in pharmaceutical manufacturing processes, which could enhance the efficiency and quality of Montelukast production. In addition, the Montelukast API Market is likely to witness a shift towards more sustainable practices. Manufacturers may explore eco-friendly production methods and raw material sourcing to align with global sustainability goals. This inclination towards sustainability could not only improve the market's public perception but also potentially attract investment from environmentally conscious stakeholders. Overall, the Montelukast API Market appears poised for growth, driven by both demand for effective treatments and a commitment to sustainable practices.
The Montelukast API Market is witnessing an increase in demand for effective treatments targeting respiratory conditions. This trend is likely fueled by heightened awareness of chronic respiratory diseases and their impact on quality of life.
Innovations in pharmaceutical manufacturing processes are shaping the Montelukast API Market. Enhanced production techniques may lead to improved efficiency and product quality, potentially benefiting both manufacturers and consumers.
There is a growing emphasis on sustainable practices within the Montelukast API Market. Manufacturers may adopt eco-friendly production methods and sourcing strategies, aligning with global sustainability initiatives and appealing to environmentally conscious consumers.
An increase in healthcare expenditure across various regions is a significant driver for the Montelukast API Market. As countries allocate more resources to healthcare, there is a corresponding rise in the availability and accessibility of medications for chronic conditions such as asthma and allergies. This trend is particularly evident in emerging economies, where healthcare reforms are aimed at improving patient outcomes. The Montelukast API Market, being a cost-effective treatment option, is likely to benefit from this increased spending. Furthermore, the emphasis on preventive healthcare and chronic disease management aligns with the therapeutic profile of Montelukast, suggesting a favorable market environment for its continued growth.
The Montelukast API Market is significantly influenced by regulatory approvals and clinical guidelines that endorse the use of Montelukast for various respiratory conditions. Regulatory bodies, such as the FDA and EMA, have established guidelines that facilitate the approval process for new formulations and generics of Montelukast. This regulatory support not only enhances market accessibility but also encourages pharmaceutical companies to invest in research and development. As a result, the market is witnessing an influx of new entrants and innovative formulations, which could potentially expand the therapeutic applications of Montelukast. The alignment of clinical guidelines with emerging research further solidifies the role of Montelukast in asthma and allergy management, thereby driving market growth.
The rising incidence of asthma and allergic conditions is a primary driver for the Montelukast API Market. According to recent data, asthma affects approximately 300 million individuals worldwide, with a notable increase in prevalence among children. This growing patient population necessitates effective treatment options, thereby propelling the demand for Montelukast, a well-established leukotriene receptor antagonist. As healthcare providers seek to manage these chronic conditions more effectively, the Montelukast API Market is likely to experience substantial growth. Furthermore, the increasing awareness of asthma management strategies among patients and healthcare professionals contributes to the heightened demand for Montelukast, reinforcing its position in the therapeutic landscape.
Technological advancements in drug delivery systems are poised to impact the Montelukast API Market positively. Innovations such as smart inhalers and sustained-release formulations enhance the efficacy and patient compliance of Montelukast. These advancements not only improve the therapeutic outcomes for patients but also create new market opportunities for pharmaceutical companies. As the industry embraces these technologies, the Montelukast API Market is likely to be integrated into more sophisticated delivery systems, thereby expanding its market reach. The potential for personalized medicine, where treatments are tailored to individual patient needs, further underscores the importance of these technological developments in shaping the future of the Montelukast API Market.
The increasing awareness and education regarding respiratory health are crucial drivers for the Montelukast API Market. Public health campaigns and educational initiatives aimed at asthma and allergy management have led to a greater understanding of these conditions among patients and healthcare providers. This heightened awareness encourages individuals to seek treatment options, including Montelukast, thereby driving demand. Additionally, healthcare professionals are more equipped to recommend Montelukast as a viable treatment option, further enhancing its market presence. The focus on respiratory health education is likely to continue, suggesting a sustained growth trajectory for the Montelukast API Market as more patients become informed about their treatment choices.
In the Montelukast API Market, the application segment is largely dominated by asthma treatment, accounting for a significant portion of the total market share. Allergic rhinitis, while smaller, has been gaining traction, driven by increasing awareness and prescription rates among healthcare providers. The other applications, including bronchospasm, urticaria, and others, contribute less to the overall shares but are essential components of the market dynamics.
Asthma (Dominant) vs. Allergic Rhinitis (Emerging)
Asthma remains the dominant application segment within the Montelukast API Market, driven by a high prevalence of the condition globally and ongoing prescription trends. On the other hand, allergic rhinitis is emerging as a significant contender due to elevated allergen exposure and enhanced public awareness regarding treatment options. The growing focus on addressing respiratory conditions alongside allergic reactions will continue to shape the market landscape, with asthma taking the lead while allergic rhinitis sees rapid growth and increased market penetration.
Get more detailed insights about Montelukast API Market Request Free Sample
North America is the largest market for Montelukast API Market, holding approximately 45% of the global market share. The region benefits from advanced healthcare infrastructure, high prevalence of asthma and allergies, and strong regulatory support from agencies like the FDA. The increasing demand for effective asthma management solutions is driving growth, alongside a rise in generic drug approvals, which enhances market accessibility. The United States is the primary contributor, with significant participation from Canada. Key players such as Merck & Co. and Teva Pharmaceutical Industries dominate the landscape, leveraging their extensive distribution networks and R&D capabilities. The competitive environment is characterized by a focus on innovation and strategic partnerships, ensuring a steady supply of Montelukast API Market to meet growing healthcare needs.
Europe is the second-largest market for Montelukast API Market, accounting for around 30% of the global share. The region's growth is propelled by increasing asthma prevalence, supportive regulatory frameworks, and a strong emphasis on generic medications. The European Medicines Agency (EMA) plays a crucial role in facilitating market entry for new generics, which enhances competition and affordability for patients. Leading countries include Germany, France, and the UK, where the presence of major pharmaceutical companies like Mylan N.V. and Sandoz International GmbH strengthens the market. The competitive landscape is marked by a mix of established players and emerging firms, all striving to capture market share through innovation and cost-effective solutions. The focus on patient-centric approaches further drives demand for Montelukast API Market in the region.
Asia-Pacific is witnessing rapid growth in the Montelukast API Market, holding approximately 20% of the global share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of asthma management, and a growing population. Countries like India and China are at the forefront, with supportive government initiatives aimed at enhancing healthcare access and affordability, which are crucial for market growth. India is a significant player, with companies like Aurobindo Pharma and Cipla Limited leading the charge in production and distribution. The competitive landscape is evolving, with both local and international firms vying for market share. The focus on cost-effective solutions and the increasing demand for generics are shaping the market dynamics, making Asia-Pacific a key region for Montelukast API Market.
The Middle East and Africa (MEA) region is gradually emerging in the Montelukast API Market, currently holding about 5% of the global share. The growth is driven by increasing healthcare investments, rising awareness of respiratory diseases, and a growing population. Regulatory bodies are beginning to implement frameworks that support the introduction of generic medications, which is expected to enhance market accessibility in the coming years. Countries like South Africa and the UAE are leading the way, with a growing number of local manufacturers entering the market. The competitive landscape is characterized by a mix of multinational corporations and regional players, all aiming to meet the rising demand for effective asthma treatments. The focus on improving healthcare infrastructure and patient access is crucial for the region's growth in the Montelukast API Market.
Leading market players are largely investing in research and development to expand their product lines, which will help the montelukast API market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their presence. The Montelukast API industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.One of the major business strategies manufacturers use in the montelukast API industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the montelukast API industry has stipulated some of the most important medicinal benefits. Major players in the montelukast API industry, including Teva Pharmaceutical Industries Ltd (Israel), Sandoz International GmbH (Germany), Vintage Pharmaceuticals Inc (US), Morepen Laboratories Ltd (India), and others, are funding operations for research and development to boost market demand.Morepen Laboratories is a renowned Pharmaceutical Company in Active Pharmaceutical Ingredients and Formulations. Morepen Laboratories Limited, founded in 1984 by Mr. KB Suri, began as a pure API manufacturer. The company manufactures and sells active formulations, pharmaceutical ingredients (APIs), and home health products. With approvals from all the major regulatory agencies, including the USFDA, WHO GMP, and EU GMP, Morepen has an important international footprint and distributes to over 75 countries.In December Morepen Laboratories announced that it had got approval from the US Food and Medicine Administration to market its anti-allergy medicine Fexofenadine Hydrochloride in the United States.In India, the medicine is marketed under the brand Allegra.Valeo Pharma Inc is a Canadian specialty pharmaceutical business focused on acquisitions, in-licensing, and similar partnerships. It now markets Synacthen Depot, a synthetic ACTH medication used in cases where natural cortisol and other hormone synthesis is needed.In March Valeo Pharma Inc. announced a Commercialization and Supply Contract with Novartis Pharmaceuticals Canada Inc. for the Canadian marketing of two asthma therapies, Enerzair Breezhaler (indacaterol (as acetate), glycopyrronium (as bromide), and mometasone furoate) and Atectura Breezhaler (indacaterol (as acetate) and mometasone furoate).
The Montelukast API Market is projected to grow at a 10.8% CAGR from 2025 to 2035, driven by increasing asthma prevalence, rising healthcare expenditure, and advancements in drug formulation.
New opportunities lie in:
By 2035, the Montelukast API Market is expected to achieve substantial growth and innovation.
| MARKET SIZE 2024 | 1.01(USD Billion) |
| MARKET SIZE 2025 | 1.119(USD Billion) |
| MARKET SIZE 2035 | 3.121(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 10.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Merck & Co. (US), Teva Pharmaceutical Industries Ltd. (IL), Mylan N.V. (NL), Sandoz International GmbH (CH), Aurobindo Pharma (IN), Cipla Limited (IN), Hikma Pharmaceuticals PLC (GB), Zydus Cadila (IN) |
| Segments Covered | Application, Region |
| Key Market Opportunities | Emerging regulatory frameworks may enhance growth prospects in the Montelukast API Market. |
| Key Market Dynamics | Rising demand for Montelukast API driven by regulatory shifts and increasing prevalence of respiratory disorders. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
The Montelukast API Market was valued at 1.01 USD Billion in 2024.
The market is projected to reach a valuation of 3.121 USD Billion by 2035.
The expected CAGR for the Montelukast API Market during 2025 - 2035 is 10.8%.
Key players in the market include Merck & Co., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sandoz International GmbH, Aurobindo Pharma, Cipla Limited, Hikma Pharmaceuticals PLC, and Zydus Cadila.
In 2024, the Asthma application segment had the highest valuation at 0.404 USD Billion.
The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, pharmaceutical industry publications, and authoritative health organizations. Key sources included:
Regulatory & Government Sources:
US Food and Drug Administration (FDA) - Orange Book, Drug Approvals Database
European Medicines Agency (EMA) - Centralized Procedure Approvals, EPARs
International Conference on Harmonisation (ICH) Guidelines
World Health Organization (WHO) Prequalification Programme
Central Drugs Standard Control Organization (CDSCO) - India
Pharmaceuticals and Medical Devices Agency (PMDA) - Japan
National Medical Products Administration (NMPA) - China
Medicines and Healthcare products Regulatory Agency (MHRA) - UK
Health Canada - Drug Product Database
Industry & Trade Organizations:
International Generic and Biosimilar Medicines Association (IGBA)
Active Pharmaceutical Ingredients Committee (APIC) - Europe
Indian Drug Manufacturers' Association (IDMA)
China Pharmaceutical Industry Association (CPIA)
European Federation of Pharmaceutical Industries and Associations (EFPIA)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Clinical & Epidemiological Sources:
National Center for Biotechnology Information (NCBI/PubMed)
Global Initiative for Asthma (GINA) Guidelines
American Academy of Allergy, Asthma & Immunology (AAAAI)
European Respiratory Society (ERS)
World Allergy Organization (WAO)
Centers for Disease Control and Prevention (CDC) - Asthma Surveillance
National Institutes of Health (NIH) - National Heart, Lung, and Blood Institute
Market & Statistical Databases:
IQVIA Institute for Human Data Science
Evaluate Pharma
Global Burden of Disease (GBD) Study Database
WHO Global Health Observatory
OECD Health Statistics
National Health Service (NHS) Digital - UK Prescription Data
These sources were used to collect API production statistics, regulatory approval data, clinical safety studies, epidemiological trends for asthma and allergic rhinitis, pricing dynamics, and competitive landscape analysis for Montelukast API across branded and generic formulations.
Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of API Manufacturing, leaders of Regulatory Affairs, and Commercial Directors from active pharmaceutical ingredient manufacturers, contract manufacturing organizations (CMOs), and finished dosage form (FDF) producers. Procurement heads from generic pharmaceutical companies, formulation development scientists, regulatory consultants, and supply chain managers from pharmaceutical distributors and hospital pharmacy networks constituted demand-side sources. The primary research validated market segmentation, confirmed manufacturing capacity expansions, and collected insights on API sourcing patterns, pricing strategies, and regulatory compliance dynamics.
Primary Respondent Breakdown:
By Company Tier:
Tier 1 (>USD 10B revenue): 38%
Tier 2 (USD 1B-10B revenue): 32%
By Designation:
C-level Executives (CEOs, CFOs, COOs): 32%
Director Level (VP, Head of Department): 31%
Others (Managers, Specialists, Consultants): 37%
By Region:
North America: 32%
Europe: 29%
Asia-Pacific: 31%
Rest of World (Latin America, MEA): 8%
By Stakeholder Type:
API Manufacturers: 45%
Generic Pharma Companies: 30%
Contract Manufacturing Organizations: 15%
Distributors/Traders: 10%
Global market valuation was derived through revenue mapping and production volume analysis. The methodology included:
Identification of 50+ key API manufacturers and formulation companies across North America, Europe, Asia-Pacific, and Latin America
Product mapping across asthma, allergic rhinitis, bronchospasm, urticaria, and other therapeutic applications
Analysis of reported and modeled annual revenues specific to Montelukast API portfolios
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (API volume × ASP by region/country) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations
Cross-validation with prescription volume data from national health databases and import/export statistics from customs authorities
This methodology is specifically tailored for the Montelukast API market, incorporating pharmaceutical industry-specific sources such as FDA Orange Book, EMA EPARs, WHO prequalification data, GINA guidelines, and API manufacturing associations, while maintaining the structural format of your original dermal fillers methodology.
Kindly complete the form below to receive a free sample of this Report
“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”
“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”
“Thanks for sending the report it gives us a good global view of the Betaïne market.”
“Thank you, this will be very helpful for OQS.”
“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”
“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”
“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”
